John Allan, MD, Weill Cornell Medicine

Articles

Novel Therapies for CLL

July 30th 2020

PI3 Kinase Inhibitors in CLL

July 30th 2020

Therapeutic Sequencing in CLL

July 30th 2020

BTK Inhibitors in Relapsed/Refractory CLL

July 30th 2020

MURANO Trial Update in R/R CLL

July 30th 2020

Utility of MRD Testing in CLL Management

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

July 30th 2020

Venetoclax and Obinutuzumab in CLL

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

July 30th 2020

BTK inhibitor With vs Without a CD20-Targeted Antibody

July 30th 2020

Second-Generation BTK Inhibitors in CLL

July 30th 2020

Therapies in the Pipeline for Frontline CLL

July 30th 2020

Telemedicine for Patients With CLL

July 30th 2020

BTK Inhibitors in CLL: Ibrutinib

July 30th 2020

Current Role for Chemoimmunotherapy in CLL

July 30th 2020

Treating CLL During COVID-19

July 30th 2020

Frontline Treatment Options in CLL

July 30th 2020

Selecting Frontline Therapy for CLL

July 30th 2020

COVID-19 and CLL Treatment Initiation

July 30th 2020